Xact Kapitalforvaltning’s Corcept Therapeutics CORT Stock Holding History

Xact Kapitalforvaltning’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$206K	Hold	17,360	–	–	﹤0.01%	1187
2019 Q4	$210K	Hold	17,360	–	–	﹤0.01%	1369
2019 Q3	$245K	Hold	17,360	–	–	﹤0.01%	1304
2019 Q2	$194K	Hold	17,360	–	–	﹤0.01%	1394
2019 Q1	$204K	Hold	17,360	–	–	﹤0.01%	1387
2018 Q4	$232K	Hold	17,360	–	–	0.01%	1376
2018 Q3	$243K	Hold	17,360	–	–	0.01%	1474
2018 Q2	$273K	Buy	17,360 +4,400	+34%	+$76.5K	0.01%	1407
2018 Q1	$213K	Hold	12,960	–	–	﹤0.01%	1459
2017 Q4	$234K	Buy	+12,960	New	+$235K	0.01%	1128

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Xact Kapitalforvaltning's CORT Position: Q1 2020 in Review

Xact Kapitalforvaltning held its Corcept Therapeutics (CORT) position steady in Q1 2020 at 17,360 shares worth $206K. The position accounts for ﹤0.01% of the portfolio, ranked #1187.

Xact Kapitalforvaltning first reported a position in CORT in Q4 2017 and has held it in 10 quarters since. The position peaked at $273K in Q2 2018. 204 funds tracked by Wall St. Rank hold CORT as of Q1 2020.

Xact Kapitalforvaltning held 17,360 shares of Corcept Therapeutics worth $206K as of Q1 2020.
Xact Kapitalforvaltning left its Corcept Therapeutics share count unchanged in Q1 2020.
Corcept Therapeutics made up ﹤0.01% of Xact Kapitalforvaltning's portfolio in Q1 2020, its #1187 holding.
Xact Kapitalforvaltning first reported a position in Corcept Therapeutics in Q4 2017 and has held it in 10 quarters since.
Xact Kapitalforvaltning's Corcept Therapeutics position peaked at $273K in Q2 2018.
204 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2020.

Based on Xact Kapitalforvaltning's 13F filing for Q1 2020, filed 14 May 2020.